Biogen-Eisai’s potential Aduhelm sequel drug granted speedy review by FDAnews2021-12-27T15:56:24+00:00December 27th, 2021|FierceBiotech|
Editor’s Corner: Fierce Biotech’s top 10 most read stories in 2021news2021-12-22T14:04:05+00:00December 22nd, 2021|FierceBiotech|
Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spreenews2021-12-22T08:29:10+00:00December 22nd, 2021|FierceBiotech|
Aiming to make 70 the new 50, Korify rolls out $100M longevity and mental health venture fundnews2021-12-22T06:50:24+00:00December 22nd, 2021|FierceBiotech|
PhaseBio blames COVID-19 disruption as cardiovascular study axednews2021-12-21T14:20:22+00:00December 21st, 2021|FierceBiotech|
Pfizer reports patient death in early-stage Duchenne gene therapy trial, halts enrollmentnews2021-12-21T13:39:57+00:00December 21st, 2021|FierceBiotech|
Abandoned by Amgen, Cytokinetics lands deal for Chinese rights to heart failure prospectnews2021-12-21T12:51:03+00:00December 21st, 2021|FierceBiotech|
Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospectnews2021-12-21T12:51:03+00:00December 21st, 2021|FierceBiotech|
Sanofi gambles $1B upfront on preclinical oncology biotech, bagging Amunix for its pipeline of T-cell engagersnews2021-12-21T12:17:23+00:00December 21st, 2021|FierceBiotech|
Chutes & Ladders—CRISPR Therapeutics bids adieu to R&D head in securities filingnews2021-12-21T12:03:57+00:00December 21st, 2021|FierceBiotech|
